Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

Amy Elizabeth DeZern, M.D., M.H.S.

Photo of Dr. Amy Elizabeth DeZern, M.D., M.H.S.
  • Associate Professor of Oncology
Female

Expertise

Acute Myeloid Leukemia (AML), Aplastic Anemia, Bone Marrow Failure, Bone Marrow Transplant, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria ...read more

Request an Appointment

Insurance Information

Maryland

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map

Background

Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. She received her medical degree in 2005 from the Johns Hopkins University School of Medicine and her Masters in Clinical Investigation (M.H.S.) from the Johns Hopkins Bloomberg School of Public Health. She completed residency training in internal medicine as well as fellowships in medical oncology and hematology at Johns Hopkins. Dr. DeZern sees patients at the Sidney Kimmel Comprehensive Cancer Center.

Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of myelodysplastic syndromes (MDS), aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), and other bone marrow failure syndromes as well as acute leukemias. She sees clinic patients weekly with these diagnoses as well as patients in need of bone marrow transplants for the same disorders. Dr. DeZern greatly enjoys taking care of patients with bone marrow failure and hematologic malignancies, and is dedicated to improving the care and outcomes of patients with these conditions. To that end, she is an active clinician scientist who specializes in clinical studies of diagnostics and therapeutics for marrow failure. She is the principal investigator of several clinical trials treating patients with severe aplastic anemia using a specialized bone marrow transplant regimen at Johns Hopkins as well as the PI of multiple other study protocols for novel therapeutics in MDS. Her work has resulted in multiple publications in the scientific literature and presentations at national meetings. She is also involved with the Aplastic Anemia and MDS International Foundation and is the local PI of the MDS Clinical Research Consortium. Additionally, she is the Deputy Chair of the National MDS Study.

...read more

Titles

  • Associate Professor of Oncology
  • Associate Professor of Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Johns Hopkins University School of Medicine (2005)

Residencies

  • Johns Hopkins University School of Medicine / Internal Medicine (2008)

Fellowships

  • Johns Hopkins University School of Medicine / Hematology and Oncology (2009)
  • Johns Hopkins University School of Medicine / Oncology (2012)

Board Certifications

  • American Board of Internal Medicine / Hematology (2013)
  • American Board of Internal Medicine / Internal Medicine (2008)

Research & Publications

Research Summary

The clinical investigation of novel approaches to diagnosis and therapy in bone marrow failure disorders and clonal hematopoiesis. Dr. DeZern leads multiple trials specifically in aplastic anemia and myelodysplastic syndrome.

Clinical Trial Keywords

Aplastic Anemia, Myelodysplastic syndrome, Bone marrow transplants, Bone marrow failure disorders, Leukemia

Selected Publications

View all on Pubmed

DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston N, Ambinder RF, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 Apr 28;4(8):1770-1779. doi: 10.1182/bloodadvances.2020001729.

Dalton WB, Helmenstine E, Pieterse L, Li B, Gocke CD, Donaldson J, Xiao Z, Gondek LP, Ghiaur G, Gojo I, Smith BD, Levis MJ, DeZern AE. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 2020 Apr 14;4(7):1192-1196. doi: 10.1182/bloodadvances.2019001127. No abstract available.

Gondek LP, DeZern AE. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3. Review.

Schratz KE, DeZern AE. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice. Hematol Oncol Clin North Am. 2020 Apr;34(2):333-356. doi: 10.1016/j.hoc.2019.10.002. Epub 2020 Jan 6. Review.

DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2017 Mar;23(3):498-504. doi: 10.1016/j.bbmt.2016.12.628. Epub 2016 Dec 21.

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button